膵外分泌不全の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測

◆英語タイトル:Exocrine Pancreatic Insufficiency Market - (Therapeutic - Pancreatic Enzyme Replacement Therapy (Creon, Zenpep, Pancreaze, Ultresa, Viokase, Pertzye) and Phase III Drugs; Diagnostic Test - Blood Tests, Endoscopic ultra-sonography, MRI, and CT Scanning) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023
◆商品コード:TMR607084
◆発行会社(調査会社):Transparency Market Research
◆発行日:2016年5月17日
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥660,630見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥1,002,630見積依頼/購入/質問フォーム
Corporate LicenseUSD11,795 ⇒換算¥1,344,630見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、膵外分泌不全の世界市場について調査・分析し、以下の構成でお届けいたします。
・膵外分泌不全の世界市場:序文
・膵外分泌不全の世界市場:エグゼクティブサマリー
・膵外分泌不全の世界市場:市場概要・動向
・膵外分泌不全の世界市場:セグメント別市場規模・分析
・膵外分泌不全の世界市場:地域別市場規模・分析
・膵外分泌不全の世界市場:関連企業分析
【レポートの概要】

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or a condition called maldigestion. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. Management of EPI is based primarily on pancreatic enzyme replacement therapy (PERT), but could also include lifestyle modifications and vitamin supplementation as appropriate. Increase in prevalence of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis accentuates the demand for exocrine pancreatic insufficiency market worldwide. The most effective treatment for exocrine pancreatic insufficiency is to successfully treat the underlying condition causing the enzyme insufficiency. Chronic pancreatitis is a benign disease often characterized by recurrent episodes of abdominal pain supplemented by progressive pancreatic exocrine and endocrine insufficiency. Treatment with antioxidants may improve quality of life and reduce pain in patients suffering from chronic pancreatitis.
This research study analyzes the market for exocrine pancreatic insufficiency (EPI) in terms of revenue (US$ Mn). The exocrine pancreatic insufficiency (EPI) market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. The report also includes key market dynamics, such as drivers, restraints, and opportunities, affecting the demand for exocrine pancreatic insufficiency (EPI) treatment products globally. Comparative analysis has also been included in the executive summary that resembles the percentage market share of each regions in 2014 and 2023 respectively.
This report provides in-depth analysis of the exocrine pancreatic insufficiency market. The stakeholders for this report include companies involved in the manufacturing of products used in treatment of exocrine pancreatic insufficiency. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions.
The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the exocrine pancreatic insufficiency market in the current and future scenario. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the exocrine pancreatic insufficiency market. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.
The exocrine pancreatic insufficiency market by therapeutic has been segmented as pancreatic enzyme replacement therapy (PERT) drugs and diagnostic tests. PERT drugs involves Creon, Zenpep, Pancreaze, Ultresa and Pertzye. The diagnostic tests involves blood tests, endoscopic ultra-sonography, magnetic resonance imaging and CT scanning.
Geography wise, the exocrine pancreatic insufficiency market has been differentiated into five major regions: North America, Asia Pacific, Europe, Latin America and Rest of the World. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., Japan China, Russia, Brazil, Mexico and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the exocrine pancreatic insufficiency market in various regions has been provided in this section.
The report provides market estimation of exocrine pancreatic insufficiency market in terms of revenue (US$ Mn) for all the segments and sub segments with CAGR % for period 2015 to 2023, considering 2014 as the base year. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2014.
The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Abbvie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. are among others.
The global exocrine pancreatic insufficiency market is segmented into the following categories:
Global Exocrine Pancreatic Insufficiency Market, by Therapeutics
• Pancreatic Enzyme Replacement Therapy (PERT) Drugs
o Creon
o Zenpep
o Pancreaze
o Ultresa
o Viokace
o Pertzye
• Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Sollpura (Liprotamase)
Global Exocrine Pancreatic Insufficiency Market, by Diagnostic Tests
• Blood Tests
• Endoscopic Ultra-Sonography (EUS)
• Magnetic Resonance Imaging (MRI)
• CT Scanning
Global Exocrine Pancreatic Insufficiency Market, by Geography
• North America
o U.S.
o Canada
o Rest of North America
• Europe
o U.K.
o Germany
o Rest of Europe
• Asia Pacific
o China
o Japan
o Rest of APAC
• Latin America
o Brazil
o Mexico
o Rest of LATAM
• Rest of the World
o South Africa
o Russia
o Rest of RoW

【レポートの目次】

1. Preface
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. Assumptions

2. Executive Summary
2.1. Market Snapshot: Exocrine Pancreatic Insufficiency, 2014 & 2023
2.2. Comparative Analysis: Exocrine Pancreatic Insufficiency Market, by Geography (%), 2014 & 2023
2.3. U.S. Exocrine Pancreatic Insufficiency Market, by Type, 2014 (US$ Mn)

3. Exocrine Pancreatic Insufficiency Market – Industry Analysis
3.1. Introduction and Market Definition
3.2. Treatment other than Drug therapy
3.3. Market Dynamics
3.4. Market Attractiveness Analysis of Global Exocrine Pancreatic Insufficiency Market, by Geography
3.5. Impact Analysis
3.6. Pipeline Analysis (Phase II and I) Tabular Presentation
3.7. Competitive Analysis

4. Global Exocrine Pancreatic Insufficiency Market– By Therapeutics 2013-2023 (US$ Mn)
4.1. Overview
4.2. Pancreatic Enzyme Replacement Therapy (PERT) Drugs
4.2.1. Creon
4.2.2. Zenpep
4.2.3. Pancreaze
4.2.4. Ultresa
4.2.5. Viokace
4.2.6. Pertzye
4.3. Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Post launch – 2023, Sollpura (Liprotamase)

5. Global Exocrine Pancreatic Insufficiency Market – By Diagnostic Tests
5.1. Overview
5.2. Blood Tests
5.3. Endoscopic Ultra-Sonography (EUS)
5.4. Magnetic Resonance Imaging (MRI)
5.5. CT Scanning

6. Global Exocrine Pancreatic Insufficiency Market – By Geography
6.1. North America
6.1.1. U.S.
6.1.2. Canada
6.1.3. Rest of North America
6.2. Europe
6.2.1. U.K.
6.2.2. Germany
6.2.3. Rest of Europe
6.3. Asia Pacific
6.3.1. China
6.3.2. Japan
6.3.3. Rest of APAC
6.4. Latin America
6.4.1. Brazil
6.4.2. Mexico
6.4.3. Rest of LATAM
6.5. Rest of the World
6.5.1. South Africa
6.5.2. Russia
6.5.3. Rest of RoW

7. Company Profiles
7.1. Abbvie Inc.
7.2. Allergan plc.
7.3. Nordmark Arzneimittel GmbH & Co. KG
7.4. Digestive Care, Inc.
7.5. Cilian AG
7.6. Anthera Pharmaceuticals Inc.
7.7. Janssen Pharmaceuticals Inc.
7.8. AzurRx BioPharma, Inc.

List of Figures

FIG. 1 Market Segmentation
FIG. 2 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2014
FIG. 3 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2023
FIG. 4 Exocrine Pancreatic Insufficiency (EPI) Market, by Type, 2014 (US$ Mn)
FIG. 5 Global Exocrine Pancreatic Insufficiency Market, by Geography, Value (%), 2014
FIG. 6 U.S. Exocrine Pancreatic Insufficiency Market, by Key Players, 2014 (%)
FIG. 7 U.S. Creon Market Revenue, (US$ Mn), 2013–2023
FIG. 8 U.S. Zenpep Market Revenue, (US$ Mn), 2013–2023
FIG. 9 U.S. Pancreaze Market Revenue, (US$ Mn), 2013–2023
FIG. 10 U.S. Ultresa Market Revenue, (US$ Mn), 2013–2023
FIG. 11 U.S. Viokace Market Revenue, (US$ Mn), 2013–2023
FIG. 12 U.S Pertzye Market Revenue, (US$ Mn), 2013–2023
FIG. 13 U.S Sollpura (Liprotamase) Market Revenue, (US$ Mn), 2013–2023
FIG. 14 Global Blood Tests Market Revenue, (US$ Mn), 2013–2023
FIG. 15 Global Endoscopic ultra-sonography (EUS) Market Revenue, (US$ Mn), 2013–2023
FIG. 16 Global Magnetic resonance imaging (MRI) Market Revenue, (US$ Mn), 2013–2023
FIG. 17 Global CT scanning Market Revenue, (US$ Mn), 2013–2023
FIG. 18 AbbVie, Inc., Annual Revenue, 2013–2015 (US$ Mn)
FIG. 19 Allergan plc Annual Revenue, 2012–2014 (US$ Mn)

List of Tables

TABLE 1 Exocrine Pancreatic Insufficiency (EPI): Market Snapshot
TABLE 2 Impact Analysis
TABLE 3 Pipeline Analysis (Phase I and II): Tabular Presentation
TABLE 4 U.S. Exocrine Pancreatic Insufficiency (EPI) Market Revenue, (US$ Mn), 2013–2023
TABLE 5 Global Exocrine Pancreatic Insufficiency Market Revenue, by Diagnostic Test, (US$ Mn), 2013–2023
TABLE 6 Global Exocrine Pancreatic Insufficiency Market Revenue, by Geography, 2013–2023
TABLE 7 North America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 8 Europe Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 9 Asia Pacific Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 10 Latin America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 11 Rest of the World (RoW) Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023



【レポートのキーワード】

膵外分泌不全

★調査レポート[膵外分泌不全の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測]販売に関する免責事項
★調査レポート[膵外分泌不全の世界市場:産業分析、市場規模、市場シェア、成長、動向、予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆